3 Vaccine, Global Generic and Ophthalmology Stocks With a Strong Future Roadmap: GlaxoSmithKline Pharmaceuticals, Aurobindo Pharma and Dr. Agarwal’s Health Care
- October 13, 2026
- Posted by: Neeraj Pandey
- Category: Best Stocks
GSK Pharma Rs 2,531.50, P/E 40.20. Aurobindo Pharma Rs 1,706.90, P/E 25.46. Dr. Agarwal’s Health Care Rs 475.20, P/E 80.51. Closing prices of 12 Oct 2026.
Quick Answer
Vaccine, global generic and ophthalmology stocks with the clearest long-term roadmaps today include GSK Pharma in branded medicines and vaccines, Aurobindo Pharma in generic formulations and active ingredients for global markets and Dr. Agarwal’s Health Care in eye care hospitals and clinics. FY26 revenue growth was 1.8% at GSK Pharma, 5.6% at Aurobindo Pharma and 20.9% at Dr. Agarwal’s Health Care. P/E stands at 40.20 for GSK Pharma (industry 37.59), 25.46 for Aurobindo Pharma (industry 37.59) and 80.51 for Dr. Agarwal’s Health Care (industry 62.79). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company’s risks need equal attention.
Vaccine, global generic and ophthalmology stocks give investors exposure to vaccines, generic medicines and eye care that patients depend on. Prescription growth, export approvals and hospital additions decide how much of that demand turns into profit.
This list covers three vaccine, global generic and ophthalmology stocks: GlaxoSmithKline Pharmaceuticals for branded medicines and vaccines, Aurobindo Pharma for generic formulations and active ingredients for global markets and Dr. Agarwal’s Health Care for eye care hospitals and clinics. Every figure comes from the latest reported financials and the 12 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Vaccine, Global Generic and Ophthalmology Stocks?
Vaccine, global generic and ophthalmology stocks are shares of companies that make vaccines and generic medicines or run specialty eye care centres. Results depend on prescription growth, export approvals and hospital additions, so growth and margins separate the stronger names.
Vaccine, Global Generic and Ophthalmology Stocks at a Glance
The table compares size, valuation, return on equity and debt for the three vaccine, global generic and ophthalmology stocks as of the 12 Oct 2026 close.
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE | Debt to Equity |
|---|---|---|---|---|---|---|
| GlaxoSmithKline Pharmaceuticals | 2,531.50 | 42,939 | 40.20 | 37.59 | 45.69% | 0.01 |
| Aurobindo Pharma | 1,706.90 | 94,477 | 25.46 | 37.59 | 9.25% | 0.21 |
| Dr. Agarwal’s Health Care | 475.20 | 14,907 | 80.51 | 62.79 | 6.58% | 0.53 |
Among healthcare stocks, GSK Pharma and Dr. Agarwal’s Health Care trade at a premium to the industry P/E, while Aurobindo Pharma trades at a discount.
Why Do Vaccine, Global Generic and Ophthalmology Stocks Have a Strong Roadmap in India?
Vaccine, global generic and ophthalmology stocks have a strong roadmap in India because rising health awareness, wider insurance cover and global demand for affordable generics keep lifting demand for these healthcare firms. Three drivers stand out.
- Vaccination: Immunisation programmes widen the user base.
- Generic exports: Global buyers prefer affordable Indian medicines.
- Specialty care: Eye care needs rise with age and screen use.
GlaxoSmithKline Pharmaceuticals: Branded Medicines and Vaccines Anchor the Roadmap
GSK Pharma’s roadmap rests on branded medicines and vaccines sold through a large doctor network, with established brands supporting steady sales.
Revenue grew from Rs 3,353.80 crore in FY22 to Rs 3,967.03 crore in FY26, an 18.3% rise, and FY26 revenue was 1.8% higher than FY25. FY26 net profit rose 11.7% to Rs 1,035.98 crore. Over four years, net profit rose from Rs 380.77 crore in FY22 to Rs 1,035.98 crore. In Q1 FY27, revenue grew 15.7% to Rs 982.20 crore, and net profit rose 15.7% to Rs 237.18 crore. Operating margin was 38.60% in FY26.
Debt to equity is 0.01 and return on equity is 45.69%. FY26 operating cash flow was Rs 903.30 crore against capital expenditure of Rs 55.28 crore. GSK Pharma paid a dividend of Rs 57 per share for FY26, a yield of 2.25%. At a P/E of 40.20 against an industry P/E of 37.59, the stock trades above its industry multiple.
What to watch: The P/E of 40.20 is a modest premium to the industry P/E of 37.59, so the next quarters’ growth is the figure to follow.
Aurobindo Pharma: Generic Formulations and Ingredients Build the Next Leg
Aurobindo Pharma’s roadmap rests on generic formulations and active ingredients sold in the US, Europe and emerging markets, with a wide product basket supporting export revenue.
Revenue grew from Rs 23,775.84 crore in FY22 to Rs 34,145.17 crore in FY26, a 43.6% rise, and FY26 revenue was 5.6% higher than FY25. FY26 net profit rose 0.6% to Rs 3,502.97 crore. Over four years, net profit rose from Rs 2,647.11 crore in FY22 to Rs 3,502.97 crore. In Q1 FY27, revenue grew 18.1% to Rs 9,414.58 crore, and net profit rose 25.2% to Rs 1,032.03 crore. Operating margin was 21.61% in FY26 and 23.10% in Q1 FY27 against 21.95% a year earlier.
Debt to equity is 0.21 and return on equity is 9.25%. FY26 operating cash flow was Rs 5,526.37 crore against capital expenditure of Rs 3,104.67 crore. Aurobindo Pharma paid a dividend of Rs 4 per share for FY26, a yield of 0.25%. At a P/E of 25.46 against an industry P/E of 37.59, the stock trades below its industry multiple.
What to watch: Q1 FY27 operating margin was 23.10% against 21.61% for FY26, so margin stability is the figure to follow as volumes grow.
Dr. Agarwal’s Health Care: A Growing Eye Care Network Drives the Pipeline
Dr. Agarwal’s Health Care’s roadmap rests on eye care hospitals and clinics across India and overseas, with a growing network of centres supporting patient volumes.
Revenue grew from Rs 713.78 crore in FY22 to Rs 2,124.52 crore in FY26, a 197.6% rise, and FY26 revenue was 20.9% higher than FY25. FY26 net profit rose 52.4% to Rs 168.14 crore. Over four years, net profit rose from Rs 43.16 crore in FY22 to Rs 168.14 crore. In Q1 FY27, revenue grew 23.9% to Rs 620.43 crore, and net profit rose 44.6% to Rs 55.02 crore. Operating margin was 29.95% in FY26.
Debt to equity is 0.53 and return on equity is 6.58%. FY26 operating cash flow was Rs 518.99 crore against capital expenditure of Rs 460.58 crore. At a P/E of 80.51 against an industry P/E of 62.79, the stock trades above its industry multiple.
What to watch: Return on equity of 6.58% is modest.
Best Vaccine, Global Generic and Ophthalmology Stocks in India: GSK Pharma vs Aurobindo Pharma vs Dr. Agarwal’s Health Care on Key Financials
Among the best vaccine, global generic and ophthalmology stocks in India, GSK Pharma leads on FY26 operating margin and return on equity; Aurobindo Pharma leads on the lowest P/E; Dr. Agarwal’s Health Care leads on FY26 revenue growth and Q1 FY27 revenue growth. The table puts the numbers side by side.
| Metric | GSK Pharma | Aurobindo Pharma | Dr. Agarwal’s Health Care |
|---|---|---|---|
| FY26 revenue (Rs Cr) | 3,967.03 | 34,145.17 | 2,124.52 |
| FY26 revenue growth | 1.8% | 5.6% | 20.9% |
| FY26 net profit (Rs Cr) | 1,035.98 | 3,502.97 | 168.14 |
| FY26 net profit growth | 11.7% | 0.6% | 52.4% |
| FY26 operating profit margin | 38.60% | 21.61% | 29.95% |
| Q1 FY27 revenue growth (YoY) | 15.7% | 18.1% | 23.9% |
| Q1 FY27 net profit growth (YoY) | 15.7% | 25.2% | 44.6% |
| Return on equity | 45.69% | 9.25% | 6.58% |
| P/E ratio | 40.20 | 25.46 | 80.51 |
| Debt to equity | 0.01 | 0.21 | 0.53 |
| Dividend yield | 2.25% | 0.25% | 0.00% |
| FY26 operating cash flow (Rs Cr) | 903.30 | 5,526.37 | 518.99 |
Healthcare earnings follow prescription growth, export approvals and hospital additions, so full-year numbers and quarterly trends together give a better view.
How to Evaluate Vaccine, Global Generic and Ophthalmology Stocks to Buy Before You Invest
A short checklist keeps the research consistent when you screen vaccine, global generic and ophthalmology stocks and shortlist vaccine, global generic and ophthalmology stocks to buy.
- Compare each stock’s P/E with its industry P/E, which differs by company here.
- Check revenue growth, operating margin and return on equity together.
- Check whether revenue growth is turning into profit growth, not only sales.
- Read operating cash flow against capital expenditure to see how growth is funded.
- Watch debt to equity and interest cover before sizing a position.
- Spread exposure across companies and business lines instead of one demand cycle.
Check the Univest Screener for live data on these vaccine, global generic and ophthalmology stocks
Risks to Consider Before Investing in Vaccine, Global Generic and Ophthalmology Stocks
- Pricing rules: Price controls and export pricing can affect margins.
- Regulation: Plant inspections can affect supply.
- Quarterly trends: A single weak quarter can change near-term earnings, so track results every quarter.
Download the Univest iOS App or Univest Android App to track GSK Pharma, Aurobindo Pharma and Dr. Agarwal’s Health Care live.
Final Take: Which Stock Has the Strongest Roadmap?
These three healthcare stocks cover vaccines, generic medicines for global markets and eye care hospitals. GSK Pharma leads on FY26 operating margin and return on equity; Aurobindo Pharma leads on the lowest P/E; Dr. Agarwal’s Health Care leads on FY26 revenue growth and Q1 FY27 revenue growth.
Across vaccine, global generic and ophthalmology stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the vaccine, global generic and ophthalmology stocks to buy discussed here.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Vaccine, Global Generic and Ophthalmology Stocks
Which are the best vaccine, global generic and ophthalmology stocks in India with a strong roadmap?
Ans. GlaxoSmithKline Pharmaceuticals, Aurobindo Pharma and Dr. Agarwal’s Health Care stand out for their roadmaps in vaccines, generic medicines for global markets and eye care hospitals. FY26 revenue growth was 1.8% at GSK Pharma, 5.6% at Aurobindo Pharma and 20.9% at Dr. Agarwal’s Health Care, and return on equity ranges from 6.58% to 45.69%.
Is GlaxoSmithKline Pharmaceuticals a good stock to buy now?
Ans. GlaxoSmithKline Pharmaceuticals has a debt to equity ratio of 0.01, a return on equity of 45.69% and a P/E of 40.20 against an industry P/E of 37.59. Valuation, growth and regulation move results. This article is not investment advice, so consult a SEBI-registered advisor before deciding.
What is the P/E ratio of GSK Pharma, Aurobindo Pharma and Dr. Agarwal’s Health Care?
Ans. The P/E ratio is 40.20 for GSK Pharma (industry 37.59), 25.46 for Aurobindo Pharma (industry 37.59) and 80.51 for Dr. Agarwal’s Health Care (industry 62.79). Only GSK Pharma and Dr. Agarwal’s Health Care trade at or above the industry multiple.
Which of these vaccine, global generic and ophthalmology stocks has the highest return on equity?
Ans. GlaxoSmithKline Pharmaceuticals has the highest return on equity at 45.69%, followed by Aurobindo Pharma at 9.25% and Dr. Agarwal’s Health Care at 6.58%.
What are the risks of investing in vaccine, global generic and ophthalmology stocks?
Ans. The main risks are pricing rules, regulation and quarterly trends. Price controls and export pricing can affect margins.
How did GSK Pharma, Aurobindo Pharma and Dr. Agarwal’s Health Care perform in Q1 FY27?
Ans. GlaxoSmithKline Pharmaceuticals reported revenue of Rs 982.20 crore, up 15.7% year on year, and net profit rose 15.7% to Rs 237.18 crore. Aurobindo Pharma reported revenue of Rs 9,414.58 crore, up 18.1% year on year, and net profit rose 25.2% to Rs 1,032.03 crore. Dr. Agarwal’s Health Care reported revenue of Rs 620.43 crore, up 23.9% year on year, and net profit rose 44.6% to Rs 55.02 crore.
Do vaccine, global generic and ophthalmology stocks pay dividends?
Ans. GSK Pharma and Aurobindo Pharma pay dividends. The dividend yield is 2.25% for GSK Pharma and 0.25% for Aurobindo Pharma, based on dividends declared for FY26.
How can I invest in vaccine, global generic and ophthalmology stocks in India?
Ans. You can buy vaccine, global generic and ophthalmology stocks through a demat and trading account on NSE or BSE after checking each company’s financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.
